- Trial phase
- Phase 3
- Time to market
- Likely several years away. The Phase 3 trial started recruiting in July 2026 with an estimated 53-month duration, so a potential regulatory filing would be no earlier than 2028-2029 barring accelerated approval based on Phase 2 data.
- Why 4/10
- ABBV-706 has no scheduled PDUFA date or pivotal readout within the next ~12 months; its Phase 3 trial (NCT07365241) began recruiting in July 2026 with an estimated 53-month duration. The drug is one of many pipeline assets at a large-cap pharma, so even a positive future readout would have a modest impact on AbbVie's stock price.
The next hard catalyst for ABBV-706 is the Phase 3 (NCT07365241) topline readout, but that is likely 2-3 years away given the trial started recruiting in July 2026. Watch for interim analysis announcements and any updates on the Phase 2 SEZanne frontline combination trial. For now, ABBV-706 is a promising but early-stage asset within AbbVie's broad pipeline, not a near-term binary event for the stock.
Price Chart
Executive Summary
ABBV-706 is AbbVie's investigational antibody-drug conjugate (ADC) targeting the SEZ6 protein, being developed primarily for relapsed/refractory small cell lung cancer (SCLC). Phase 1 data presented at ASCO and ESMO 2026 showed a 56% objective response rate at the recommended Phase 3 dose (1.8 mg/kg) and 82% ORR in second-line patients, with median overall survival of 12.4 months. The drug received FDA Orphan Drug Designation for SCLC in October 2024. A global Phase 3 trial (NCT07365241) comparing ABBV-706 against standard of care began recruiting in July 2026 with a target of 531 patients, and a Phase 2 SEZanne trial is evaluating ABBV-706 plus atezolizumab in frontline extensive-stage SCLC. However, ABBV-706 faces strong competition from Amgen's already-approved Imdelltra (tarlatamab), which recently posted Phase 3 data showing a 58% reduction in death risk. As one of many pipeline assets at a ~$520B large-cap pharma, ABBV-706 has no near-term binary catalyst for AbbVie's stock.
How It Works
ABBV-706 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: one part of the drug (the antibody) seeks out and binds to a protein called SEZ6 found on the surface of small cell lung cancer and certain other tumor cells. Once attached, the drug releases a chemotherapy payload (a topoisomerase 1 inhibitor) directly inside the cancer cell, killing it while largely sparing healthy cells. The drug-to-antibody ratio is 6, meaning each antibody carries six payload molecules.
Trial Status
A global Phase 3 randomized trial (NCT07365241) comparing ABBV-706 against standard of care (topotecan, lurbinectedin, or amrubicin) in relapsed/refractory SCLC began recruiting in July 2026, targeting 531 patients across ~175 sites in 10 countries. A Phase 2 SEZanne trial (NCT07155174) is evaluating ABBV-706 combined with atezolizumab in frontline extensive-stage SCLC. Phase 1 monotherapy data (NCT05599984) has been published in Nature Medicine and presented at ASCO and ESMO 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 (NCT07365241) interim or final topline readout, likely 2-3 years out
- Phase 2 SEZanne trial (ABBV-706 + atezolizumab in frontline ES-SCLC) updates
- Potential regulatory filing if AbbVie pursues accelerated approval based on Phase 1/2 data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report